# A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

Study · id `cardio:ct-nct03066804` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03066804](<https://clinicaltrials.gov/study/NCT03066804>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03066804

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2572 participants.

## Technical summary

Registry record NCT03066804. Randomized; quadruple masking; primary purpose treatment. Start 2017-08-22 (actual); primary completion 2019-10-28 (actual). Results posted on 2021-02-08.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 2572 participants (enrolled count; ClinicalTrials.gov record NCT03066804, source copy `cardio:ctgov-nct03066804-2021-10-11`, retrieved 2026-10-26)
- Started: 2017-08-22 (actual) (ClinicalTrials.gov record NCT03066804, source copy `cardio:ctgov-nct03066804-2021-10-11`, retrieved 2026-10-26)
- Primary completion: 2019-10-28 (actual) (ClinicalTrials.gov record NCT03066804, source copy `cardio:ctgov-nct03066804-2021-10-11`, retrieved 2026-10-26)
- Completion: 2019-10-28 (actual) (ClinicalTrials.gov record NCT03066804, source copy `cardio:ctgov-nct03066804-2021-10-11`, retrieved 2026-10-26)
- Results first posted: 2021-02-08 (ClinicalTrials.gov record NCT03066804, source copy `cardio:ctgov-nct03066804-2021-10-11`, retrieved 2026-10-26)
- Countries: United States; Argentina; Austria; Belgium; Brazil; Bulgaria; Canada; Colombia; Czechia; Denmark; Estonia; France; Germany; Guatemala; Hungary; India; Israel; Italy; Latvia; Lithuania; Mexico; Netherlands; Peru; Portugal; Romania; Russia; Serbia; Slovakia; Spain; Thailand; Türkiye; United Kingdom (ClinicalTrials.gov record NCT03066804, source copy `cardio:ctgov-nct03066804-2021-10-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03066804-2021-10-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
- Acronym: PARALLAX
- Condition: Heart Failure With Preserved Ejection Fraction
- Intervention (Drug): sacubitril/valsartan
- Intervention (Drug): Enalapril
- Intervention (Drug): Valsartan
- Intervention (Drug): Placebo to match sacubitril/valsartan
- Intervention (Drug): Placebo to match enalapril
- Intervention (Drug): Placebo to match valsartan
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition term reads as this condition, and the trial is coded with its broader condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry intervention name matches this record: Enalapril (`cardio:enalapril`)
- Registry intervention name matches this record: Valsartan (`cardio:valsartan`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial (`cardio:pubmed-34783839`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f94ccf9799aa3711e9a8b9ee77ac19243202ef59d83cf4e71998f7a5661b0ce6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
